

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		vvasnington, D.C. 20231		
SERIAL NUMBER FILING DATE	NUMBER FILING DATE FIRST NAMED APPLICANT		ATTORNEY DOCKET NO	
07/229,489 08/08/88	TAKAYA	т <u>1</u> :	8-511-0	
OPLON, FISHER, SFIVAK, MC CLELLAND & MAIER		FIZZO, N		
CRYSTAL SQUARE FIVE - 9 1755 SOUTH JEFFERSON DA		ART UNIT	PAPER NUMBER	
ARLINGTON, VA 22202		122	3	
		DATE MAILED:	05.44.405	

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been exami	ned Responsive to commun	cation filed on	This action is made final.
A shortened statutory period for reso	oonse to this action is set to expire	3 month(s) — day	in from the date of their letter
	for response will cause the application		
L Notice of References Cit  Notice of Art Cited by A	ACHMENT(S) ARE PART OF THIS AC ted by Examiner, PTO-892. pplicant, PTO-1449	2. Notice re Patent 4. Notice of informa	Drawing, PTO-948. I Patent Application, Form PTO-152
5. Information on How to Ef	fect Drawing Changes, PTO-1474	E. 🗌	
Part II SUMMARY OF ACTION			
1. Claims	9	- · · · · · · · · · · · · · · · · · · ·	are pending in the application.
Of the above, clai	ims		are withdrawn from consideration.
2. Claims	***************************************		have been cancelled.
4. Claims	7		are rejected.
5. Claims			are objected to.
6. Claims		are sub	ject to restriction or election requirement.
7. This application has been matter is indicated.	n filed with informal drawings which a	re acceptable for examination :	purposes until such time as allowable subject
8. [ Allowable subject matter	having been indicated, formal drawing	s are required in response to t	his Office action.
9. The corrected or substitute. In not acceptable (see	ete drawings have been received on	The:	se drawings are 🛅 acceptable;
	g correction and/or the [] proposed a proved by the examiner, [] disapprov		o) of drawings, filed on
the Patent and Trademark	k Office no longer makes Grawing chan <u>(UST</u> be effected in accordance with th	ges. It is now applicant's ies	in disapproved (see explanation). However, possibility to ensure that the drawings are attached letter "INFORMATION ON HOW TO
12. Acknowledgment is made	of the claim for priority under 35 U.S.	C. 119. The certified copy ha	been received in not been received
! j been filed in parent	application, serial no.	; filed on	
•	pears to be in condition for allowance tice under Exparte Quayle, 1935 C.D		secution as to the ments is closed in

Serial No. 07/229489

Art Unit 122

The claims are 1-9.

The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

-2-

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 1-9 are rejected under 35 U.S.C. 103 as being unpatentable over Takaya 4,559,334.

Different forms of the same compound are presumptively non-patentable. See ex parte forms 139USPQ525 and the cases cited therein. The cephalosporin compounds are known to be more useful in the crystalline form, see Merck index page 268 (copy enclosed). Thus, preparing the crystalline form of a human ompound follows the teachings of the art, which is evidence of obviousness, not unobviousness. See in al 128 USPQ 116.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicholas Rizzo whose telephone number is (703) 557-3981.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 557-3920.

RIZZO:drb A/C 703 557-3920 5/9/89